Top Markets
Coin of the day
Sangui Biotech International, Inc. Sangui Biotech International, Inc.

Sangui Biotech International, Inc.

SGBI
Rang in aandelen #41118
Sangui Biotech International, Inc., through its subsidiary Sangui BioTech GmbH,... Sangui Biotech International, Inc., through its subsidiary Sangui BioTech GmbH, specializes in creating artificial oxygen carriers derived from hemoglobin. These innovative products are utilized as blood supplements, blood volume replacements, and various related formulations. The company's oxygen carriers are vital for delivering oxygen to humans experiencing acute or chronic oxygen deprivation due to conditions like blocked arteries, anemia, or blood loss, as well as for managing chronic wounds. Their product line also includes nano-formulations designed for skin regeneration, enhancing moisture and elasticity. Furthermore, they provide Chitoskin wound pads to aid in healing and Hemospray, a medical-grade spray specifically formulated for treating persistent wounds. The wound spray products, marketed under the Granulox brand, are primarily distributed in Europe and Mexico, while their cosmetic items are available through an online store. Established in 1995, Sangui Biotech International, Inc. is based in Hamburg, Germany.
Aandeelprijs
$0.0002
Laatst gesynchroniseerd: 2025-07-02
Marktkapitalisatie
$41.98K
Verandering (1 dag)
0.00%
Verandering (1 jaar)
0.00%
Land
DE
Handel Sangui Biotech International, Inc. (SGBI)

Categorie

Winst voor Sangui Biotech International, Inc. (SGBI)
Winst in 2026 TTM: 0
Volgens de meest recente financiële verslagen van Sangui Biotech International, Inc. bedraagt de huidige winst van het bedrijf 0. In 2026 behaalde het bedrijf een winst van 0, gelijk aan de winst van 2026, die 0 bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Sangui Biotech International, Inc. van 2026 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
Niet genoeg gegevens voor de verstrekte datums.
Winst van vergelijkbare bedrijven of concurrenten